Find a trial

PACT Update

As with everything since early 2020, pulmonary fibrosis clinical trials and PACT activities have been majorly impacted by the global pandemic. We are continuing to operate as normally as possible during this challenging time. Thank you to all involved in the ongoing clinical response to COVID-19. We are excited to continue supporting important pulmonary fibrosis trials in Australasia. To stay up to date, become a member.

Become a member

Deciding to be part of a clinical trial is a very personal decision. People eligible to participate in a clinical trial are limited to a group with very specific characteristics. Please see below clinical trials that are currently recruiting in Australasia.

Recruiting Trials

Trial	Title	Status	More Information
Roche WA42293	A phase III randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of PRM-151 in patients with Idiopathic Pulmonary Fibrosis.	Recruiting	Trial Summary Clinicaltrials.gov ID: NCT04552899
GALACTIC-1	A randomised, double-blind, multicentre, parallel, placebo-controlled Phase 2b study in participants with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of GB0139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler (DPI) over 52 weeks.	Recruiting	Trial Summary Clinicaltrials.gov ID: NCT03832946
BMS IM027-040	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis.	Recruiting	Trial Summary Clinicaltrials.gov ID: NCT04308681
TELO-SCOPE	Attenuating Telomere Attrition with Danazol. Is there Scope to Dramatically Improve Health Outcomes for Adults and Children with Pulmonary Fibrosis.	Recruitment pending	Trial Summary Clinicaltrials.gov ID: NCT04638517
Zephyrus	FGCL-3019-091 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis (IPF).	Recruiting	Trial Summary Clinicaltrials.gov ID: NCT03955146
AGN120-1	An Open Label Study of the Efficacy, Safety and Tolerablity of Np-120 on Idiopathic Pulmonary Fibrosis and its Associated Cough	Recruiting	Trial Summary Clinicaltrials.gov ID: NCT04318704
PFOX	PFOX: Pulmonary Fibrosis Ambulatory Oxygen Trial	Recruiting	Trial Summary Clinicaltrials.gov ID: NCT03737409
HIIT	High intensity interval training in fibrotic interstitial lung disease	Recruiting	Trial Summary Clinicaltrials.gov ID: NCT03800914
GRIPF	Genetic research in Idiopathic Pulmonary Fibrosis (GRIPF)	Recruiting	Trial Summary Not Applicable

Trials in Follow Up

Trial	Title	Status	More Information
BI 1305-0013	Title: A randomised, double-blind, placebo-controlled parallel group study in IPF patients over 12 weeks evaluating efficacy, safety and tolerability of BI 1015550 taken orally.	Closed to Recruitment	Trial Summary Clinicaltrials.gov ID: NCT04419506
ATLAS	A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis	Closed to recruitment	Trial Summary Clinicaltrials.gov ID: ACTRN12618001838202
Trail1	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease (RAILD)	Closed to recruitment	Trial Summary Clinicaltrials.gov ID: NCT02808871

Completed Trials

Trial	Title	Status	More Information
HHF-ILD	Handheld fan for breathlessness in interstitial lung disease	Study completed	Trial Summary Clinicaltrials.gov ID: ACTRN12618001949279
COLDICE	Cryobiopsy versus Open Lung biopsy in the Diagnosis of Interstitial lung disease allianCE	Study completed	Trial Summary Clinicaltrials.gov ID: ACTRN12615000718549
SPIRIT	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis (IPF)	Study completed	Trial Summary ClinicalTrials.gov ID: NCT03573505

Discontinued Trials

Trial	Title	Status	More Information
SCENIC	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial	Discontinued The SCENIC study was terminated due to the impact of COVID-19. The study was being conducted across 11 countries and while the impact was minimal in Australasia this was not the case in the other regions.	Trial Summary Clinicaltrials.gov ID: NCT03864328
Isabela 1&2	A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects With ldiopathic Pulmonary Fibrosis	Discontinued The decision to discontinue the ISABELA Phase 3 clinical studies was based on the recommendations of the Independent Data Monitoring Committee (IDMC) which, following a regular review of unblinded data, concluded that ziritaxestat’s benefit-risk profile no longer supported continuing these studies. Detailed data of the ISABELA studies will be presented at future medical meetings.	Trial Summary Clinicaltrials.gov ID: NCT0371l-162 Clinicaltrials.gov ID: NCT03733444